Model-based sensitivity analysis for outcome reporting bias in the meta analysis of benefit and harm outcomes

被引:12
作者
Copas, John [1 ]
Marson, Anthony [2 ]
Williamson, Paula [3 ]
Kirkham, Jamie [3 ]
机构
[1] Univ Warwick, Dept Stat, Coventry CV4 7AL, W Midlands, England
[2] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England
[3] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England
基金
英国医学研究理事会;
关键词
Outcome reporting bias; meta analysis; selective reporting; Outcome Reporting Bias in Trials classification; REFRACTORY PARTIAL EPILEPSY; PLACEBO-CONTROLLED TRIAL; DOSE-RANGING TRIAL; DOUBLE-BLIND; TOPIRAMATE; METAANALYSIS; SEIZURES; THERAPY; IMPACT;
D O I
10.1177/0962280217738546
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Outcome reporting bias occurs when outcomes in research studies are selectively reported, the selection being influenced by the study results. For benefit outcomes, we have shown how risk assessments using the Outcome Reporting Bias in Trials risk classification scale can be used to calculate bias-adjusted treatment effect estimates. This paper presents a new and simpler version of the benefits method, and shows how it can be extended to cover the partial reporting and non-reporting of harm outcomes. Our motivating example is a Cochrane systematic review of 12 studies of Topiramate add-on therapy for drug-resistant partial epilepsy. Bias adjustments for partially reported or unreported outcomes suggest that the review has overestimated the benefits and underestimated the harms of the test treatment.
引用
收藏
页码:889 / 903
页数:15
相关论文
共 28 条
  • [1] Alderson P, 2011, COCHRANE DB SYST REV, V12
  • [2] Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures
    BenMenachem, E
    Henriksen, O
    Dam, M
    Mikkelsen, M
    Schmidt, D
    Reid, S
    Reife, R
    Kramer, L
    Pledger, G
    Karim, R
    [J]. EPILEPSIA, 1996, 37 (06) : 539 - 543
  • [3] Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
    Chan, AW
    Krieza-Jeric, K
    Schmid, I
    Altman, DG
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (07) : 735 - 740
  • [4] Coles H, 1999, EPILEPSIA, V40, P285
  • [5] A model-based correction for outcome reporting bias in meta-analysis
    Copas, John
    Dwan, Kerry
    Kirkham, Jamie
    Williamson, Paula
    [J]. BIOSTATISTICS, 2014, 15 (02) : 370 - 383
  • [6] Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias - An Updated Review
    Dwan, Kerry
    Gamble, Carrol
    Williamson, Paula R.
    Kirkham, Jamie J.
    [J]. PLOS ONE, 2013, 8 (07):
  • [7] A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children
    Elterman, RD
    Glauser, TA
    Wyllie, E
    Reife, R
    Wu, SC
    Pledger, G
    [J]. NEUROLOGY, 1999, 52 (07) : 1338 - 1344
  • [8] Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages
    Faught, E
    Wilder, BJ
    Ramsay, RE
    Reife, RA
    Kramer, LD
    Pledger, GW
    Karim, RM
    Barr, A
    Fischer, J
    Bergen, D
    Boor, D
    Browne, T
    Davenport, J
    Dichter, M
    Drake, M
    Kuzniecky, R
    Mamdani, M
    McCutchen, C
    Naritoku, D
    Potolicchio, S
    Ramani, V
    Ramsay, R
    Shinnar, S
    So, E
    Wilder, B
    [J]. NEUROLOGY, 1996, 46 (06) : 1684 - 1690
  • [9] Low-dose topiramate in adults with treatment-resistant partial-onset seizures
    Guberman, A
    Neto, W
    Gassmann-Mayer, C
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2002, 106 (04): : 183 - 189
  • [10] Hardy RJ, 1996, STAT MED, V15, P619, DOI 10.1002/(SICI)1097-0258(19960330)15:6<619::AID-SIM188>3.0.CO